Application submitted to the EMA for use of Pradaxa® in treatment of DVT and PE and prevention of recurrent DVT and PE
24 June 2013 | By Boehringer Ingelheim
Boehringer Ingelheim announced the submission of an application to the EMA...
List view / Grid view
24 June 2013 | By Boehringer Ingelheim
Boehringer Ingelheim announced the submission of an application to the EMA...
26 April 2013 | By Daiichi Sankyo
Daiichi Sankyo to support and co-sponsor phase 1 Clinical Study...
21 February 2013 | By Boehringer Ingelheim
Findings from two trials...
8 December 2012 | By Bristol-Myers Squibb Company
Results of the Phase 3 AMPLIFY-EXT trial...
25 October 2012 | By Daiichi Sankyo
Edoxaban is an investigational, once daily, novel oral factor Xa inhibitor...
13 November 2011 | By Pfizer
Bristol-Myers Squibb Company and Pfizer Inc. announced the results of the Phase 3 ADOPT trial...
20 May 2011 | By Bristol-Myers Squibb Company
The European Commission has approved ELIQUIS® in the 27 countries of the EU...